JP Morgan Maintains Overweight on Evolent Health, Raises Price Target to $6

Benzinga Newsdesk www.benzinga.com Positive 59.6%

Neg 0% Neu 0% Pos 59.6%

JP Morgan analyst John Stansel maintains Evolent Health (NYSE:EVH) with a Overweight and raises the price target from $5 to $6.